USA Today: Why volunteer for a vaccine clinical trial? Duty, love and a willingness to experiment, participants say
First patient dosed in UC/UC Health vaccine trial says his son was a major motivation to volunteer
In a story about people who volunteer for COVID-19 vaccine trials, USA Today featured Jarelle Marshall, a 37-year-old IT professional from Cincinnati. He was the first patient to be dosed as part of the UC and UC Health trial of the Moderna COVID-19 vaccine trial.
A UC pharmacist prepares a dose for the COVID-19 vaccine trial. Photo/Colleen Kelley/UC Creative + Brand
Marshall said his 14-year-old son was a big part of his motivation to volunteer. "I always tell my son that what matters is what you do when people aren't looking," he said.
That's why when a friend asked him to participate in the trial, he didn't hesitate long. First, he asked for more information, which he forwarded to another friend, a doctor, to ask for advice. The doctor sent him a long text, telling him what to expect in the trial and why volunteers were important. Then came the kicker: Researchers need African-Americans like you.
Read the entire article here, and read more about the UC/UC Health COVID-19 vaccine trial here.
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
An expert pieced together this Roman document like a puzzle
September 1, 2026
National media highlighted a new project by UC Classics Assistant Professor Matthijs Wibier to piece together and translate an ancient Roman text from fragments buried in the desert for more than 1,600 years.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.